Background: ALRN-6924 is a cell-permeating, stabilized alpha-helical peptide that binds with
high affinity to endogenous p53 inhibitors MDM2 and MDMX. Treatment with ALRN-6924
increases intracellular p53 levels and initiates its transcriptional activity, leading
to cell cycle arrest. This effect is limited to cells with wild-type, functional p53;
therefore, for patients with tumors harboring mutated P53, pre-treatment with ALRN-6924
may selectively induce cell cycle arrest in normal cells allowing chemotherapy to
selectively target cancer cells which are actively cycling.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2020 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
